| The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism. | The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism.
Remmerie M, Dok R, Wang Z, Omella JD, Alen S, Cokelaere C, Lenaerts L, Dreesen E, Nuyts S, Derua R, Janssens V. | 10/15/2024 |
| BRG1 promotes progression of B-cell acute lymphoblastic leukemia by disrupting PPP2R1A transcription. | BRG1 promotes progression of B-cell acute lymphoblastic leukemia by disrupting PPP2R1A transcription.
Kang Q, Ma D, Zhao P, Chai X, Huang Y, Gao R, Zhang T, Liu P, Deng B, Feng C, Zhang Y, Lu Y, Li Y, Fang Q, Wang J., Free PMC Article | 08/28/2024 |
| Novel Variants of PPP2R1A in Catalytic Subunit Binding Domain and Genotype-Phenotype Analysis in Neurodevelopmentally Delayed Patients. | Novel Variants of PPP2R1A in Catalytic Subunit Binding Domain and Genotype-Phenotype Analysis in Neurodevelopmentally Delayed Patients.
Qian Y, Jiang Y, Wang J, Li G, Wu B, Zhou Y, Xu X, Wang H., Free PMC Article | 10/6/2023 |
| PPP2R1A neurodevelopmental disorder is associated with congenital heart defects. | PPP2R1A neurodevelopmental disorder is associated with congenital heart defects.
Baker EK, Solivio B, Pode-Shakked B, Cross LA, Sullivan B, Raas-Rothschild A, Chorin O, Barel O, Bar-Yosef O, Husami A, Hopkin RJ, Prada CE, Stottmann RW, Weaver KN. | 10/15/2022 |
| Chk1 Inhibition Ameliorates Alzheimer's Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling. | Chk1 Inhibition Ameliorates Alzheimer's Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling.
Hu W, Wang Z, Zhang H, Mahaman YAR, Huang F, Meng D, Zhou Y, Wang S, Jiang N, Xiong J, Westermarck J, Lu Y, Wang J, Wang X, Shentu Y, Liu R., Free PMC Article | 07/2/2022 |
| Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. | Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
O'Connor CM, Taylor SE, Miller KM, Hurst L, Haanen TJ, Suhan TK, Zawacki KP, Noto FK, Trako J, Mohan A, Sangodkar J, Zamarin D, DiFeo A, Narla G., Free PMC Article | 03/12/2022 |
| The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction. | The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction.
Lenaerts L, Reynhout S, Verbinnen I, Laumonnier F, Toutain A, Bonnet-Brilhault F, Hoorne Y, Joss S, Chassevent AK, Smith-Hicks C, Loeys B, Joset P, Steindl K, Rauch A, Mehta SG, Chung WK, Devriendt K, Holder SE, Jewett T, Baldwin LM, Wilson WG, Towner S, Srivastava S, Johnson HF, Daumer-Haas C, Baethmann M, Ruiz A, Gabau E, Jain V, Varghese V, Al-Beshri A, Fulton S, Wechsberg O, Orenstein N, Prescott K, Childs AM, Faivre L, Moutton S, Sullivan JA, Shashi V, Koudijs SM, Heijligers M, Kivuva E, McTague A, Male A, van Ierland Y, Plecko B, Maystadt I, Hamid R, Hannig VL, Houge G, Janssens V., Free PMC Article | 07/10/2021 |
| Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1. | Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
Kauko O, Imanishi SY, Kulesskiy E, Yetukuri L, Laajala TD, Sharma M, Pavic K, Aakula A, Rupp C, Jumppanen M, Haapaniemi P, Ruan L, Yadav B, Suni V, Varila T, Corthals GL, Reimand J, Wennerberg K, Aittokallio T, Westermarck J., Free PMC Article | 12/12/2020 |
| R183W mutant of PPP2R1A, the gene encoding the PP2A Aalpha scaffolding subunit, failed to suppress tumor growth in vivo through activation of the MAPK pathway in RAS-mutant transformed cells. Cells expressing R183W were less sensitive to MEK inhibitors. Results demonstrate that the R183W mutation in PPP2R1A potentiates oncogenic signaling and reduces drug sensitivity of RAS-mutant cells to MEK inhibitors. | Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, Brautigan DL, Haider S, Jackson M, Narla G., Free PMC Article | 06/20/2020 |
| Association of the rs10406151 C variant with AD risk appears to involve brain PPP2R1A gene expression alterations. | Association of PPP2R1A with Alzheimer's disease and specific cognitive domains.
Miron J, Picard C, Labonté A, Auld D, Breitner J, Poirier J, United Kingdom Brain Expression Consortium, PREVENT-AD research group. | 05/9/2020 |
| In addition, 6 other cancer-associated genes (BRAF, NRAS, HRAS, ERK1, ERK2 and PTEN) were also analyzed. In total, four somatic mutations were identified in three out of 101 ovarian endometriotic lesions (4%, 4/101), including a KRAS p.G12V, a PPP2R1A p.S256F and two ARID1A nonsense mutations (p.Q403* and p.G1926*); while no mutations were identified in the remaining 7 genes (BRAF, NRAS, HRAS, ERK1, ERK2, PTEN and PIK3CA) | The presence of KRAS, PPP2R1A and ARID1A mutations in 101 Chinese samples with ovarian endometriosis.
Zou Y, Zhou JY, Guo JB, Wang LQ, Luo Y, Zhang ZY, Liu FY, Tan J, Wang F, Huang OP. | 02/23/2019 |
| PP2A controls mitotic exit through EG5 dephosphorylation. | Protein Phosphatase 2A (PP2A) Regulates EG5 to Control Mitotic Progression.
Liu Y, Zhang Z, Liang H, Zhao X, Liang L, Wang G, Yang J, Jin Y, McNutt MA, Yin Y., Free PMC Article | 12/22/2018 |
| RAB9 competes with the catalytic subunit PPP2CA in binding to PPP2R1A. This competitive association has an important role in controlling the PP2A catalytic activity. | A subset of RAB proteins modulates PP2A phosphatase activity.
Sacco F, Mattioni A, Boldt K, Panni S, Santonico E, Castagnoli L, Ueffing M, Cesareni G., Free PMC Article | 07/21/2018 |
| Total PP2A activity and PPP2R1A-associated PP2Ac activity were significantly increased in cells overexpressing PPP2R1A-WT. In addition, overexpression of PPP2R1A-WT increased cell proliferation in vitro and tumor growth in vivo | Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway.
Jeong AL, Han S, Lee S, Su Park J, Lu Y, Yu S, Li J, Chun KH, Mills GB, Yang Y., Free PMC Article | 05/5/2018 |
| PPP2R1A mutations occur in a subset of gastrointestinal stromal tumors and are associated with a high malignant potential that leads to decreased disease-free survival and overall survival | Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
Toda-Ishii M, Akaike K, Suehara Y, Mukaihara K, Kubota D, Kohsaka S, Okubo T, Mitani K, Mogushi K, Takagi T, Kaneko K, Yao T, Saito T. | 01/13/2018 |
| Results demonstrated that the promotive effect of eEF-2K on glycolysis resulted from the kinase-mediated restriction of synthesis of the protein phosphatase 2A-A (PP2A-A). | eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis.
Cheng Y, Ren X, Yuan Y, Shan Y, Li L, Chen X, Zhang L, Takahashi Y, Yang JW, Han B, Liao J, Li Y, Harvey H, Ryazanov A, Robertson GP, Wan G, Liu D, Chen AF, Tao Y, Yang JM. | 09/16/2017 |
| PPP2R1A mutation is associated with endometrial carcinoma progression and abdominopelvic metastasis. | The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.
Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM, Staby KM, Rosenberg M, Stefansson IM, Kusonmano K, Chevalier A, Mauland KK, Trovik J, Krakstad C, Giannakis M, Hodis E, Woie K, Bjorge L, Vintermyr OK, Wala JA, Lawrence MS, Getz G, Carter SL, Beroukhim R, Salvesen HB., Free PMC Article | 09/9/2017 |
| PPP2R1A mutations affect PP2A function and oncogenic signaling, illuminating the genetic basis for serous EC development. | Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
Haesen D, Abbasi Asbagh L, Derua R, Hubert A, Schrauwen S, Hoorne Y, Amant F, Waelkens E, Sablina A, Janssens V. | 08/5/2017 |
| PR65A phosphorylation regulates PP2A complex signaling. | PR65A phosphorylation regulates PP2A complex signaling.
Kotlo K, Xing Y, Lather S, Grillon JM, Johnson K, Skidgel RA, Solaro RJ, Danziger RS., Free PMC Article | 11/8/2014 |
| Our results suggest that IH-induced ROS generation increases PP2A activation and subsequently downregulates ERK1/2 activation, which results in inhibition of PC12 cell proliferation through G0/G1 phase arrest and NGF-induced neuronal differentiation. | Intermittent hypoxia-induced protein phosphatase 2A activation reduces PC12 cell proliferation and differentiation.
Chen TI, Chiu HW, Pan YC, Hsu ST, Lin JH, Yang KT., Free PMC Article | 09/13/2014 |
| The two functional variants in PPP2R1A and PPP2R5E and their combinations are associated with lung cancer risk in the Chinese. | Functional genetic polymorphisms in PP2A subunit genes confer increased risks of lung cancer in southern and eastern Chinese.
Yang R, Yang L, Qiu F, Zhang L, Wang H, Yang X, Deng J, Fang W, Zhou Y, Lu J., Free PMC Article | 08/9/2014 |
| Partial unfolding of PR65/A impacts catalysis by altering the proximity of bound catalytic subunit and substrate. | Complex energy landscape of a giant repeat protein.
Tsytlonok M, Craig PO, Sivertsson E, Serquera D, Perrett S, Best RB, Wolynes PG, Itzhaki LS., Free PMC Article | 06/28/2014 |
| For PPP2R1A, a heterozygous, somatic mutation (c.771G>T, p.W257C) was identified in 1 out of 37 patients (2.7%) with primary ovarian endometrioid carcinoma. | Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.
Wang F, Zou Y, Liu FY, Yu XH, Huang H, Zhang N, Qi YY, Liu RF, Liu XY, Chen J, Huang OP, He M. | 11/16/2013 |
| gene transcription of PPP2R1A regulated by the polymorphism and methylation in the promoter region | Role of a novel functional variant in the PPP2R1A promoter on the regulation of PP2A-Aalpha and the risk of hepatocellular carcinoma.
Chen HF, Mai JR, Wan JX, Gao YF, Lin LN, Wang SZ, Chen YX, Zhang CZ, Zhang YJ, Xia B, Liao K, Lin YC, Lin ZN., Free PMC Article | 10/19/2013 |
| This study indicates that the PPP2R1A mutation occurs at a lower frequency compared to other gynecological malignancies, irrespective of the histological subtype | PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M, Nakayama K, Rahman MT, Nakayama N, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Otsuki Y, Nakayama S, Miyazaki K. | 06/1/2013 |